Recombinant Human PARK2 293 Cell Lysate
Cat.No. : | PARK2-3433HCL |
- Specification
- Gene Information
- Related Products
Description : | Antigen standard for Parkinson disease (autosomal recessive, juvenile) 2, parkin (PARK2), transcript variant 3 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. |
Source : | HEK 293 cells |
Species : | Human |
Components : | This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). |
Size : | 0.1 mg |
Storage Instruction : | Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment. |
Applications : | ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane. |
Gene Name : | PARK2 parkinson protein 2, E3 ubiquitin protein ligase (parkin) [ Homo sapiens ] |
Official Symbol : | PARK2 |
Synonyms : | PARK2; parkinson protein 2, E3 ubiquitin protein ligase (parkin); Parkinson disease (autosomal recessive, juvenile) 2, parkin; E3 ubiquitin-protein ligase parkin; AR JP; E3 ubiquitin ligase; parkin; PDJ; parkin 2; parkinson disease protein 2; parkinson juvenile disease protein 2; PRKN; AR-JP; LPRS2; |
Gene ID : | 5071 |
mRNA Refseq : | NM_004562 |
Protein Refseq : | NP_004553 |
MIM : | 602544 |
UniProt ID : | O60260 |
Chromosome Location : | 6q25.2-q27 |
Pathway : | Adaptive Immune System, organism-specific biosystem; Alpha-synuclein signaling, organism-specific biosystem; Antigen processing: Ubiquitination and Proteasome degradation, organism-specific biosystem; Class I MHC mediated antigen processing & presentation, organism-specific biosystem; Immune System, organism-specific biosystem; |
Function : | PDZ domain binding; acid-amino acid ligase activity; chaperone binding; kinase binding; ligase activity; metal ion binding; protein binding; protein kinase binding; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; zinc ion binding; |
Products Types
◆ Recombinant Protein | ||
PARK2-516C | Recombinant Cynomolgus Monkey PARK2 Protein, His (Fc)-Avi-tagged | +Inquiry |
PARK2-3935R | Recombinant Rat PARK2 Protein, His (Fc)-Avi-tagged | +Inquiry |
PARK2-6497M | Recombinant Mouse PARK2 Protein, His (Fc)-Avi-tagged | +Inquiry |
PARK2-2405Z | Recombinant Zebrafish PARK2 | +Inquiry |
PARK2-5021H | Recombinant Human PARK2, His-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionBesides Parkinson's disease, PARK2 mutations have been linked to other neurodegenerative disorders, expanding the clinical implications of studying this protein.
Yes, drug development efforts are underway to modulate PARK2 activity and enhance its neuroprotective functions as a potential therapeutic approach for Parkinson's disease.
PARK2 research provides crucial insights into the role of mitochondrial dynamics in neurodegenerative diseases, helping unravel the mechanisms underlying these disorders and paving the way for targeted therapies.
Genetic testing can help identify individuals with PARK2 mutations, allowing for personalized treatment strategies tailored to their specific genetic profile.
PARK2 is implicated in controlling inflammation in the brain, and its dysfunction may contribute to neuroinflammatory processes observed in Parkinson's disease.
Customer Reviews (3)
Write a reviewTheir expertise and commitment to customer satisfaction make them a trusted partner in achieving research goals.
Their knowledgeable team is readily available to address any questions or concerns, guaranteeing a smooth experimental process.
the manufacturer of PARK2 protein provides excellent technical support, ensuring prompt assistance and guidance.
Ask a Question for All PARK2 Products
Required fields are marked with *
My Review for All PARK2 Products
Required fields are marked with *
Inquiry Basket